Skip to main content

Part of the book series: Developments in Cardiovascular Medicine ((DICM,volume 72))

  • 85 Accesses

Abstract

Urapidil is a vasodilator effective in treatment of hypertension and congestive heart failure. Its mechanism of action combines effects resembling those of prazosin and Clonidine. It is a substituted phenylpiperazine.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Schoetensack W, et al: Tierexperimentelle Untersuchungen über den Einflx ß des Antihypertensivums Urapidil auf den Kreislauf unde die Kreislaufregulation. Arzneimittelforsch 27:1908, 1977.

    PubMed  CAS  Google Scholar 

  2. Schmucker P, et al: Therapie des Low-output-syndroms mit Urapidil und Dobutamin. Anaesthesist 30:22, 1981.

    PubMed  CAS  Google Scholar 

  3. Wang RYC, et al: Acute hemodynamic and myocardial metabolic effects of intravenous Urapidil in severe heart failure. Eur Heart J 5:745, 1984.

    PubMed  CAS  Google Scholar 

  4. Gless KH, et al: Die Wirkung von intravenös appliziertem Urapidil auf den Blutdruck bei Patienten mit krisenhaft erhöhtem Blutdruck. Therapiewoche 28:6266, 1978.

    Google Scholar 

  5. Bruckschen EG, Haerlin R: Hochdrucktherapie mit Ebrantil®. Therapiewoche 30:7850, 1980.

    Google Scholar 

  6. Schoetensack W, et al: Urapidil. In: Scriabine A (ed) New drugs annual: cardiovascular drugs. Raven, New York, 1983, p 19.

    Google Scholar 

  7. Krönig B, et al: Telemetrische Langzeitmessungen zur pharmakologischen Beeinflu ß barkeit des Belastungsblutdrucks Hochdruckkranker. Byk Gulden, Konstanz, Germany (data on file), 1973.

    Google Scholar 

  8. Bachour G: Antihypertensiver Urapidil-Effekt bei Ergometrie. In:Kaufmenn W, Bruckschen EG (eds) Proceedings of the 1st symposium on Urapidil, 20 and 21 November 1981, Bad Kreuznach, Germany. Excerpta Medica, Amsterdam, 1982, p 190.

    Google Scholar 

  9. Ludwig G, et al: Pharmakokinetik und Metabolismus des Antihypertensivums Urapidil bei Ratte und Hund. Arzneimittelforsch 27:2077, 1977.

    PubMed  CAS  Google Scholar 

  10. Kukovetz WR, et al: Humankinetik und Metabolitenmuster von Urapidil. Arzneimittelforsch 27:2406, 1977.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

Copyright information

© 1987 Martinus Nijhoff Publishing, Boston

About this chapter

Cite this chapter

Schneeweiss, A., Schettler, G. (1987). Urapidil. In: Cardiovascular Drug Therapy in the Elderly. Developments in Cardiovascular Medicine, vol 72. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-2063-0_17

Download citation

  • DOI: https://doi.org/10.1007/978-1-4613-2063-0_17

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4612-9225-8

  • Online ISBN: 978-1-4613-2063-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics